Novel Combinatory Cancer Therapy

Offentlig prosjektsammendrag

The ComboCure project primary objective is to achieve an advanced cancer drug combination ready for starting full GMP/GLP regulatory documentation. Solid tumours will be chosen as the first indication. The major research activities are non-regulatory stability studies, solubility studies on existing active compounds, chemical and pharmaceutical studies, and biological studies of new compounds including testing on enzymes, cells and in animal models. Globally there were more than million new cancer cases and 10 million cancer deaths in 2022. Beside the tremendous burden on patients and families, there is a significant impact on the global economy with annual costs of cancer of approximately 2 trillion USD. We have shown that AP7404 when used alone inhibits our target enzyme in micro-molar concentrations. ComboCure represents a novel combination of metabolic drugs that can be used alone or in combination with other established cancer treatments such as immunotherapy for the treatment of advanced forms of various cancers. The drug combination can be brought to market in one of two business models; raising the necessary equity funds to bring the drug to market, or engage in a strategic partnership with a major or medium size pharmaceutical company.